Table 5

Univariate analysis of survival

HR95% CIp Value
Age (years)1.0180.973 to 1.0650.35
Male sex1.0830.50 to 2.3450.84
Duration of symptoms before admission (days)0.8930.824 to 0.9690.0066
Smoking index (pack-years)0.99950.9989 to 1.00010.14
IPF/non-IPF1.0240.501 to 2.0910.95
Extent of ground-glass opacity (%)1.0140.990 to 1.0390.23
Extent of honeycombing (%)1.0311.004 to 1.060.023
CLE (±)0.3560.153 to 0.8290.017
PSE (±)0.7850.392 to 1.5740.50
Lymphocyte (/μL)0.99960.9990 to 1.00020.22
CRP (mg/dL)0.99290.947 to 1.0410.77
KL-6 (U/mL)1.0000.9996 to 1.00040.88
SP-D (ng/mL)1.00050.9992 to 1.00190.43
BNP (pg/mL)1.0010.9992 to 1.00280.27
D-dimer (mg/mL)0.9760.921 to 1.0450.49
PCT (ng/mL)1.8891.063 to 3.5450.030
Pao2:Fio2 ratio on admission0.9920.987 to 0.9970.0038
Pao2:Fio2 ratio on the day after glucocorticoid pulse therapy0.9890.984 to 0.9941.75×10−5
SIRS (±)11.853.551 to 39.545.78×10−5
Number of SIRS criteria1.981.448 to 2.7071.87×10−5
  • Cox proportional hazards regression models were used for the statistical analysis.

  • BNP, brain natriuretic peptide; CLE, centrilobular emphysema; CRP, C reactive protein; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen-6; PCT, procalcitonin; PSE, paraseptal emphysema; SIRS, systemic inflammatory response syndrome; SP-D, surfactant protein D.